Cargando…

Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies

BACKGROUND: Inhaled corticosteroids (ICS) are widely used and recommended to treat chronic obstructive pulmonary disease (COPD). While generally considered safe, several studies demonstrated an increased risk of pneumonia with the use of ICS in COPD patients. Although all ICS indicated for COPD carr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lodise, Thomas P, Li, Jingyi, Gandhi, Hitesh N, O’Brien, Gerald, Sethi, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667513/ https://www.ncbi.nlm.nih.gov/pubmed/33204085 http://dx.doi.org/10.2147/COPD.S269637

Ejemplares similares

Response to the Letter to the Editor Regarding “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Response to Letter]
por: Lodise, Thomas P, et al.
Publicado: (2021)

Reply to: “Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies” [Letter]
por: Barnes, Neil C, et al.
Publicado: (2021)

Comparison of fluticasone propionate and budesonide on COPD macrophage and neutrophil function
por: Belchamber, Kylie BR, et al.
Publicado: (2018)

Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate
por: Provost, Karin A., et al.
Publicado: (2019)

Budesonide and fluticasone and adrenal suppression
por: Fouda, Mona A, et al.
Publicado: (2012)

Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD
por: Janson, Christer, et al.
Publicado: (2017)

Budesonide and fluticasone propionate differentially affect the airway epithelial barrier
por: Heijink, I. H., et al.
Publicado: (2016)

Comparison of Risk of Pneumonia Caused by Fluticasone Propionate versus Budesonide in Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study
por: Choi, Jae-Hwa, et al.
Publicado: (2021)

Fluticasone propionate and increased risk of pneumonia in COPD: is it PAFR-dependent?
por: Sohal, Sukhwinder Singh
Publicado: (2017)

Comparison of viscous budesonide and fluticasone in the treatment of patients with eosinophilic esophagitis: a systematic review and meta-analysis
por: Numan, Laith, et al.
Publicado: (2023)

Intraclass grouping in the elementary school
por: Petty, Mary Clare
Publicado: (1912)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting
por: Perrone, Valentina, et al.
Publicado: (2016)

Adrenal suppression in children treated with swallowed fluticasone and oral viscous budesonide for eosinophilic esophagitis
por: Ahmet, Alexandra, et al.
Publicado: (2016)

Efficacy of indacaterol 75 μg versus fixed-dose combinations of formoterol-budesonide or salmeterol-fluticasone for COPD: a network meta-analysis
por: Cope, Shannon, et al.
Publicado: (2012)

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting [Corrigendum]
Publicado: (2017)

Salmeterol/fluticasone combination in the treatment of COPD
por: Chung, K F
Publicado: (2006)

Comparison of the effect of high-dose inhaled budesonide and fluticasone on adrenal function in patients with severe chronic obstructive pulmonary disease
por: Fahim, Ahmed, et al.
Publicado: (2012)

Umeclidinium/Vilanterol Compared with Fluticasone Propionate/Salmeterol, Budesonide/Formoterol, and Tiotropium as Initial Maintenance Therapy in Patients with COPD Who Have High Costs and Comorbidities
por: Kalhan, Ravi, et al.
Publicado: (2021)

Health Care Utilization and Costs After Initiating Budesonide/Formoterol Combination or Fluticasone/Salmeterol Combination Among COPD Patients New to ICS/LABA Treatment
por: Davis, Jill R., et al.
Publicado: (2016)

Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study
por: Wu, Zhimin, et al.
Publicado: (2020)

Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study
por: Wu, Zhimin, et al.
Publicado: (2020)

Efficacy of intranasal fluticasone propionate and budesonide in management of allergic rhinitis—a prospective comparative study
por: Shankari, P. Kiruba, et al.
Publicado: (2021)

Onset of action of indacaterol in patients with COPD: Comparison with salbutamol and salmeterol-fluticasone
por: Balint, Beatrix, et al.
Publicado: (2010)

The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial
por: Dalby, Chris, et al.
Publicado: (2009)

Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management
por: Daley-Yates, Peter, et al.
Publicado: (2023)

A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation
por: Ringdal, N., et al.
Publicado: (1996)

24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
por: Lipson, David A., et al.
Publicado: (2020)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Intraclass correlation – A discussion and demonstration of basic features
por: Liljequist, David, et al.
Publicado: (2019)

In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices
por: Nave, Ruediger, et al.
Publicado: (2007)

Adrenal suppression in an asthmatic presenting after change from high dose inhaled fluticasone propionate to inhaled budesonide
por: Abdurahman, Zainab B, et al.
Publicado: (2010)

Beclomethasone Has Lesser Suppressive Effects on Inflammation and Antibacterial Immunity Than Fluticasone or Budesonide in Experimental Infection Models
por: Kamal, Faisal, et al.
Publicado: (2020)

Correction to: Assessing the Effects of Changing Patterns of Inhaled Corticosteroid Dosing and Adherence with Fluticasone Furoate and Budesonide on Asthma Management
por: Daley-Yates, Peter, et al.
Publicado: (2023)

Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review
por: Dyer, Matthew J, et al.
Publicado: (2006)

Efficacy of treatment with montelukast, fluticasone propionate and budesonide liquid suspension for the prevention of recurrent asthma paroxysms in children with wheezing disorders
por: Ding, Bo, et al.
Publicado: (2019)

Budesonide/formoterol combination in COPD: a US perspective
por: Sharafkhaneh, Amir, et al.
Publicado: (2010)

Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Screening for data clustering in multicenter studies: the residual intraclass correlation
por: Wynants, Laure, et al.
Publicado: (2013)

Intraclass Clustering-Based CNN Approach for Detection of Malignant Melanoma
por: Bandy, Adrian D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uuj1bknadlaqsa747a1n1t3vek